Skip to content

comparison of the effect of intravenous and subcutaneous dexamethasone on the prevention of pain after cesarean section

comparison of the effect of intravenous and subcutaneous Dexamethasone on prevention of pain after caesarian section

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220430054707N1
Enrollment
156
Registered
2022-08-11
Start date
2022-09-06
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post operative caesarian pain. Onset (spontaneous) of labor after 37 completed weeks of gestation but before 39 completed weeks gestation, with delivery by (planned) cesarean section

Interventions

Intervention 1: Intervention 1: Eight milligrams of intravenous dexamethasone produced by Abidi Pharmaceutical Factory will be given as a single dose immediately after spinal anesthesia. Intervention

Sponsors

Zanjan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Candidate for non-emergency cesarean section Not having allergy to dexamethasone Age between20-45 Not having contraindications to spinal anesthesia

Exclusion criteria

Exclusion criteria: Prolongation of cesarean section more than 2 hours Convert spinal anesthesia to general for any reason.

Design outcomes

Primary

MeasureTime frame
Pain after surgery. Timepoint: During the first 24 hours after surgery, patients' pain will be assessed every 2 hours for six hours and then every six hours. Method of measurement: The pain intensity of patients will be measured using a visual analog measurement system (VAS).

Secondary

MeasureTime frame
?Apgar of neonate. Timepoint: First, Fifth and Ten minutes after birth. Method of measurement: Using the newborn Apgar scoring system.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBatoul Ahmadi

Zanjan University of Medical Sciences

Ahmadi.batoul@zums.ac.ir+98 24 3313 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026